Form 4: Vigil Neuroscience Director Vitorovic Receives Stock Option Award

Director Stefan Vitorovic of Vigil Neuroscience, Inc. was granted a stock option award for 18,068 shares on June 5, 2024.

Summary

• Stefan Vitorovic, a director at Vigil Neuroscience, Inc., received a stock option award on June 5, 2024.
• The award is for 18,068 shares of common stock.
• The exercise price of the option is $3.38 per share.
• The options vest on the earlier of June 5, 2025, or the next annual meeting of the Issuer's stockholders.
• The option expires on June 5, 2034.

Sentiment

Score: 7

Explanation: The document indicates a standard compensation practice, suggesting a neutral to slightly positive sentiment as it aligns director interests with company performance.

Positives

• The stock option award aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

NA

Industry Context

Stock option awards are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry, to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options to incentivize their directors and key employees.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term value creation.

Stakeholder Impact

• The stock option award could potentially increase shareholder value if the director's performance leads to company growth.
• The award incentivizes the director to make decisions that benefit the company and its stakeholders.

Key Dates